Novel eicosanoid pathways: the discovery of prostacyclin/6-keto prostaglandin F1alpha and the hepoxilins.
This article reviews a lecture I was honored to present at the Leon Wolfe Symposium in Montreal on March 25, 2004. The lecture described my research career, which started with my interaction with Wolfe at the Montreal Neurological Institute as a postdoctoral fellow and research associate and was followed by additional research discoveries after I left Montreal for my first academic position at the Research Institute, The Hospital for Sick Children and University of Toronto. The article consists of two parts. The first part involves the discovery (in Wolfe's laboratory) of a new pathway of arachidonic acid, in which a bicyclic prostanoid structure (later called prostacyclin by John Vane and his group) was described, and its further development in Toronto, which led to the discovery of the conversion of the bicyclic prostanoid into 6-keto prostaglandin F1alpha. The second part deals with the hepoxilin pathway, a pathway I discovered during a sabbatical leave in Japan with Professor Shozo Yamamoto, which was followed by a stay of several months in the laboratory of Professor Bengt Samuelsson in Sweden. I deal with the historical aspects of both pathways and end with interesting novel aspects of hepoxilin stable antagonist analogs in the treatment of solid tumors in experimental animals.
Pace-Asciak
Cecil R
CR
Research Institute, The Hospital for Sick Children, Programme in Integrative Biology, Toronto, Ontario, Canada M5G1X8. pace@sickkids.ca
D015121:6-Ketoprostaglandin F1 alpha / Q000502:physiology*; D000818:Animals; D015777:Eicosanoids / Q000502:physiology*; D006893:Hydroxyeicosatetraenoic Acids / Q000502:physiology*
D015777:Eicosanoids; D006893:Hydroxyeicosatetraenoic Acids; D015121:6-Ketoprostaglandin F1 alpha